ArticleAnti-cancer agents in medicinal chemistry2025
From Bench to Bioactivity: Pyranopyrazole Synthesis, Anticancer, Antimicrobial Efficacy, DFT, Molecular Docking, and Molecular Dynamic Insights.
Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rational design and antibacterial assessment of novel pyranopyrazole derivatives: a combined experimental and in silico study.Scientific reports · 2026Article
- Benzo[ACS omega · 2026Article
- Design, Synthesis, Antimicrobial and Antitumor Activities of Benzo[f]chromene Derivatives: DFT and Molecular Docking.Anti-cancer agents in medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHeterocyclic compounds are prevalent in nature and essential to life. The synthesis and application of medium-sized ring heterocyclic compounds have gained prominence. Pyranopyrazole is one such compound that has a significant impact on biological and medicinal chemistry. It has attracted interest in agrochemical research due to its fungicidal, bactericidal, and herbicidal properties. Additionally, it exhibits various biological activities, including anti-inflammatory, analgesic, antidiabetic, antimicrobial, anticancer, and antimalarial effects. Furthermore, it has been explored for its potential in treating SARS-CoV-2.
objectiveThe study synthesized novel pyranopyrazole compounds and evaluated their anticancer efficacy against certain tumor cell lines (MCF-7, HeLa, and PC-3) and antimicrobial activities as deduced through molecular docking studies.
methodsA one-pot, four-component reaction involving ethyl acetoacetate (1), hydrazine hydrate (2), malononitrile or ethyl cyanoacetate (3a, b), and aromatic aldehydes (4a-c) in an ethanolic/piperidine solution was conducted, yielding pyranopyrazoles (5a-f) in moderate to good yields.
resultsThis study involved the synthesis of novel pyranopyrazole derivatives 5a-f and the evaluation of their anticancer and antimicrobial activities. These findings indicate that compound 5f is extremely active. It is more potent than 5-fluorourcail and ofloxacin, and it may also have new modes of action that are worth more research, while compound 5d has the highest antimicrobial activity. Molecular docking studies help us learn more about how these chemicals interact with biological targets like the TGF-βI receptor and the choline-binding domain, both of which play a key role in the growth of cancer.
conclusionA series of novel pyranopyrazole derivatives 5a-f were synthesized and analyzed using spectral data. Compound 5f stands out as a lead molecule for more study and improvement due to its low IC50 value and high binding affinity. Based on how stable it is in molecular dynamics (MD) simulations and how its anticancer properties are linked to its binding affinities, it may be a strong TGF-βI receptor inhibitor.
Indexed as
Identifiers
40129153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.